HUE025369T2 - CD38 elleni humán ellenanyagok és alkalmazásuk - Google Patents

CD38 elleni humán ellenanyagok és alkalmazásuk Download PDF

Info

Publication number
HUE025369T2
HUE025369T2 HUE11196172A HUE11196172A HUE025369T2 HU E025369 T2 HUE025369 T2 HU E025369T2 HU E11196172 A HUE11196172 A HU E11196172A HU E11196172 A HUE11196172 A HU E11196172A HU E025369 T2 HUE025369 T2 HU E025369T2
Authority
HU
Hungary
Prior art keywords
antibody
seq
epitope
cell
fragment
Prior art date
Application number
HUE11196172A
Other languages
English (en)
Inventor
Michael Tesar
Ute Jäger
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37054659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE025369(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of HUE025369T2 publication Critical patent/HUE025369T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)

Claims (9)

  1. CBM ILLENI HUMÁN EUJÏNANYAGOK ÈS ALKALMAZÁSUK Szabadalmi igénypontok t. tate vagy taaaaiÄ ellenanyag vagy ûægmsme, amely CDM :egy epkópjátóz spedfíkusan kötó-db gnrigérikötö régiót tartalmaz, ahal m epitóp a következő aminosavszakaszok kőztíi választott egy vagy több amitósavszsánxszhan lévő egy vagy több aminosavat tartalmaz: CD 38 (SEQ ÏD 140:22) 44-66» 82-94.la2-lS4, 148-164, 158-Π0 vagy 192-266 mmosavszakaszai.
  2. 2. Az 1. igénypont szerinti ellenanyag vagy tógmense, aha! az epitóp a CD 3Í ÇSEQ ÎD140:22} 44-őS vagy 14S-Í64 affiiaösavszafeaszaibaa levé egy vagy több amlnosavat iaöalntaz,
  3. 3. Az 1. igénypont szerinti ellenanyag vagy fiagraense, ahol az epitóp a CD 38 (SEQ1D 240:22} 192-206 mimssavszakaszában lévő egy vagy több aminosavat iartahsaz,
  4. 4. Az l. igénypont «érinti ellenanyag vagy fegmensey ahol az epitóp a CD 3S (SEQ ID 340:22) 82-94 vagy 158-170 asniaosavszakaszaiban lévő egy vagy' több aminosavat tartalmaz.
  5. 5. Az l. igénypont szerinti ellenanyag vagy fragniense, ahol az epitóp a CD 38 (SEQ ID 240:22} 82-94 vagy 142-154 ainínosavszakaszalban lévő egy vagy több aminosavat tartalmaz.
  6. 6. Az 1-5. igés^önibk: bármelyike szeritbi ellenanyag vagy íragmense, ahol az epitóp lineáris epitóp:.
  7. 7. Az 1-5. igénypontok bármelyike szériád ellenanyag vagy fragmense, ahol az: epitóp kö«fo*mácíós epitóp. & Az 1:-7, igénypontok bármelyike szermti ellenanyag vagy fragmease, ától az ellenanyag IgO. 9. A 8. igénypont szerinti ellenanyag vagy íragmense, ahol az ellenanyag IgQl, Ibi. Az 1-9. igénypontok bármelyike szerinti ellenanyag vagy forgtnease, ától az ellenanyag szintetikus humán ellenanyag.
  8. 14,, Nuklesasav, amely az 1-10. igénypontok bármelyéke szerinti ellenanyagot vagy fragmeasét kódolja.
    12, Yekíor, amely 11. igénypont szerintinakleinsavat tartalmaz. !3. Sejt, amely 12. igénypont ssernjts vekfert Drtabnaz. 14. A 13. igénypont szerinti sejt, atnely bakteriutnsejt vagy emlőssejt. 15, gyógyászati készítmény, amely íariátmaz 1-10. igénypontok bármelyike Szeritó ellenanyagot vagy és gyógyászatijáé elfogadható tórdozót vágy segédanyagét, Id. A«· 1-18. fénypontok bármelyike szerion ellenanyag vagy fankdönális fipgmeose; alkidmazása he? matológiai betegség kezelésére szolgáló gyógyászati készítmény előállítására.
  9. 17. Az 1-10. igénypontok Mmtelyikébea megbatározott lámán ellenanyag vagy ImkeSonálls tógmppse, hematológiai betegség kezelésére: szolgáié eljárásban történő alkalmazásra, 15, A 16. igénypont szermti alkalmazás vagy a 17 igénypont: szerinti htnaán ellenanyag: vagy ftmkoíőná·· lis Ifagmeasé az ott meghatározott alkalmazásra, ahol a hematológiai betegség mÿéîoma maiíiplex, krónikás limfötd lénkérma, fcrósrikus őri elold leukémia, akut mielokl lenkémía vagy akut itólokf leuk&nía.
HUE11196172A 2004-02-06 2005-02-07 CD38 elleni humán ellenanyagok és alkalmazásuk HUE025369T2 (hu)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54191104P 2004-02-06 2004-02-06
US54758404P 2004-02-26 2004-02-26
US55394804P 2004-03-18 2004-03-18
US59901404P 2004-08-06 2004-08-06
US61447104P 2004-10-01 2004-10-01

Publications (1)

Publication Number Publication Date
HUE025369T2 true HUE025369T2 (hu) 2016-02-29

Family

ID=37054659

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11196172A HUE025369T2 (hu) 2004-02-06 2005-02-07 CD38 elleni humán ellenanyagok és alkalmazásuk

Country Status (19)

Country Link
EP (3) EP2915820A1 (hu)
JP (4) JP2008504013A (hu)
KR (2) KR20140066259A (hu)
BR (1) BRPI0507489A (hu)
CY (1) CY1116458T1 (hu)
DK (2) DK1720907T3 (hu)
ES (2) ES2541489T3 (hu)
HK (1) HK1097859A1 (hu)
HR (1) HRP20150641T1 (hu)
HU (1) HUE025369T2 (hu)
IL (1) IL177242A (hu)
ME (1) ME02245B (hu)
NO (1) NO20063986L (hu)
NZ (1) NZ548990A (hu)
PL (1) PL2511297T3 (hu)
PT (1) PT2511297E (hu)
RS (1) RS54056B1 (hu)
SG (1) SG142330A1 (hu)
WO (1) WO2005103083A2 (hu)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
SI2511297T1 (sl) 2004-02-06 2015-07-31 Morphosys Ag Proti -CD38 humana protitelesa in njihova uporaba
RS54056B1 (en) 2004-02-06 2015-10-30 Morphosys Ag ANTI-CD38 HUMAN ANTIBODIES AND THEIR USES
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
EP2535355B1 (en) 2005-03-23 2019-01-02 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
KR101472250B1 (ko) * 2005-10-12 2014-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
EA035459B1 (ru) 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
EP2039766A4 (en) * 2006-06-05 2010-06-16 Univ Hiroshima IMMUNOCOMPETENT CELL HAVING ANTI-CD38 ANTIBODY ON ITS SURFACE
NZ576122A (en) 2006-09-26 2012-09-28 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2013209322A1 (en) * 2006-10-19 2013-08-15 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
WO2010079189A1 (en) 2009-01-09 2010-07-15 Morphosys Ag Display vectors and methods and uses thereof
WO2011154453A1 (en) 2010-06-09 2011-12-15 Genmab A/S Antibodies against human cd38
HUE031956T2 (hu) 2010-09-27 2017-08-28 Morphosys Ag Anti-CD38 ellenanyag és lenalidomid vagy bortezomib multiplex mielóma és NHL kezelésére
MX2013003828A (es) * 2010-10-05 2013-06-28 Daiichi Sankyo Co Ltd Anticuerpo dirigido a la proteina lectina tipo inmunoglobulina de union a acido sialico-15 relacionada con osteoclastos.
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
EP3559049A4 (en) 2011-10-28 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd POLYPEPTIDE CONSTRUCTS AND APPLICATIONS THEREOF
MX368288B (es) 2012-09-25 2019-09-27 Morphosys Ag Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple.
WO2014068114A1 (en) 2012-11-05 2014-05-08 Morphosys Ag Radiolabelled antibody and uses thereof
JP2014117191A (ja) * 2012-12-13 2014-06-30 Fisheries Research Agency リン酸化中性スフィンゴミエリナーゼ１、抗リン酸化中性スフィンゴミエリナーゼ１抗体、中性スフィンゴミエリナーゼ１変異体、及びそれらの用途
EP2943511B1 (en) 2013-01-14 2019-08-07 Xencor, Inc. Novel heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
MX370377B (es) 2013-04-29 2019-12-11 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-cd38 y fusiones con interferón alfa-2b atenuado.
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
CN105873953A (zh) 2013-11-04 2016-08-17 格兰马克药品股份有限公司 重靶向t细胞的异源二聚免疫球蛋白的产生
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
JP6775422B2 (ja) * 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
US10106620B2 (en) 2014-06-16 2018-10-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells
WO2015195555A1 (en) 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
JP6707531B2 (ja) 2014-09-09 2020-06-10 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体による併用療法
JP6730271B2 (ja) 2014-10-29 2020-07-29 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド インターフェロンα２Ｂバリアント
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3223845B1 (en) 2014-11-26 2021-05-19 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd20
JP6802791B2 (ja) 2014-12-04 2020-12-23 ヤンセン バイオテツク，インコーポレーテツド 急性骨髄性白血病の治療のための抗ｃｄ３８抗体
WO2016164656A1 (en) * 2015-04-08 2016-10-13 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd38
EP3294769B1 (en) 2015-05-13 2021-01-13 MorphoSys AG Treatment for multiple myeloma (mm)
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
IL292708B1 (en) 2015-05-30 2024-04-01 Molecular Templates Inc Vaccine-free Shiga toxin A subunit scaffolds and cell-targeting molecules containing them
CA2990406A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
DK3313441T3 (da) 2015-06-24 2024-04-15 Janssen Biotech Inc Immunmodulering og behandling af faste tumorer med antistoffer, der specifikt binder cd38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
MD3827845T2 (ro) 2015-11-03 2022-09-30 Janssen Biotech Inc Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
KR102427948B1 (ko) 2016-03-04 2022-08-02 모르포시스 아게 다발성 골수종에서 m-단백질 반응의 임상 평가
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
US10478497B2 (en) 2016-07-20 2019-11-19 Hybrigenics S.A. Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer
CA3066547A1 (en) 2017-06-08 2018-12-13 Black Belt Therapeutics Limited Cd38 modulating antibody
CA3067311A1 (en) 2017-06-20 2018-12-27 Sorrento Therapeutics, Inc. Cd38 antibody drug conjugate
JP7301757B2 (ja) 2017-06-26 2023-07-03 バイスクルアールディー・リミテッド 検出可能部分を持つ二環式ペプチドリガンドおよびその使用
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
CN111032086B (zh) 2017-08-16 2023-09-26 黑带医疗有限公司 Cd38抗体
BR112020007002A2 (pt) * 2017-10-10 2020-11-17 Sanofi anticorpos anti-cd38 e métodos de uso
KR20200079293A (ko) 2017-10-31 2020-07-02 얀센 바이오테크 인코포레이티드 고위험 다발성 골수종을 치료하는 방법
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
US20230158070A1 (en) 2018-01-30 2023-05-25 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
CN110144008B (zh) 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810320D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38
BR112021007227A2 (pt) 2018-10-17 2021-08-10 Janssen Biotech, Inc. método para fornecer administração subcutânea de anticorpos anti-cd38
AU2019383017A1 (en) 2018-11-20 2021-06-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
MX2021007047A (es) 2018-12-14 2021-10-26 Morphosys Ag Formulaciones de anticuerpos.
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
GB201900530D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for CD38
CA3130132A1 (en) 2019-03-15 2020-09-24 Morphosys Ag Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
BR112021023295A2 (pt) 2019-05-23 2022-02-08 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
KR20220026586A (ko) 2019-06-27 2022-03-04 크리스퍼 테라퓨틱스 아게 암 치료를 위한 키메라 항원 수용체 t세포 및 nk세포 억제제의 용도
CN114729383A (zh) 2019-07-02 2022-07-08 弗莱德哈钦森癌症研究中心 重组ad35载体及相关基因疗法改进
TW202110485A (zh) 2019-07-30 2021-03-16 英商拜西可泰克斯有限公司 異質雙環肽複合物
US20220023344A1 (en) 2020-06-26 2022-01-27 Crispr Therapeutics Ag Allogeneic cell therapy of acute lymphoblastic leukemia using genetically engineered t cells targeting cd19
CN114075283A (zh) * 2020-08-12 2022-02-22 三生国健药业（上海）股份有限公司 结合人cd38的抗体、其制备方法和用途
CN114195893A (zh) * 2020-09-17 2022-03-18 百奥泰生物制药股份有限公司 抗整联蛋白抗体或抗原结合片段及其应用
GB202016331D0 (en) 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
WO2022137186A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
CA3204187A1 (en) 2021-01-14 2022-07-21 Stefan Steidl Anti-cd38 antibodies and their uses
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
AU2022232375A1 (en) 2021-03-09 2023-09-21 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
WO2022238963A2 (en) 2021-05-12 2022-11-17 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating solid tumors
AR125851A1 (es) 2021-05-12 2023-08-16 Crispr Therapeutics Ag Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en el tratamiento de neoplasias malignas hematopoyéticas
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療
US20230134748A1 (en) 2021-11-03 2023-05-04 Janssen Biotech, Inc. Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
WO2023098813A1 (en) * 2021-12-03 2023-06-08 Nanjing Leads Biolabs Co., Ltd. Antibodies binding cd38 and uses thereof
WO2023144303A1 (en) 2022-01-31 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
WO2024079010A1 (en) 2022-10-10 2024-04-18 F. Hoffmann-La Roche Ag Combination therapy of a gprc5d tcb and cd38 antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) * 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
JP2000316578A (ja) * 1999-05-12 2000-11-21 Bml Inc 糖尿病発症危険因子の検出方法
DK1144607T5 (da) 1999-07-20 2009-10-05 Morphosys Ag Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
EP1174440A1 (en) * 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
DE60237969D1 (de) * 2001-04-24 2010-11-25 Bayer Corp Menschliche antikörper gegen timp-1
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
RS54056B1 (en) * 2004-02-06 2015-10-30 Morphosys Ag ANTI-CD38 HUMAN ANTIBODIES AND THEIR USES
US20090123950A1 (en) 2005-05-24 2009-05-14 Morphosys Ag Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38
PT1978993T (pt) 2005-10-31 2017-03-17 Oncomed Pharm Inc Composições e métodos para diagnóstico e tratamento do cancro com base em recetores fzd humanos
JP2012022417A (ja) * 2010-07-12 2012-02-02 Humony Co Ltd 電子請求処理サービスシステム及び該電子請求処理サービスシステム用のアプリケーション
JP6257929B2 (ja) * 2013-06-13 2018-01-10 東芝メディカルシステムズ株式会社 Ｘ線コンピュータ断層撮影装置

Also Published As

Publication number Publication date
IL177242A (en) 2011-09-27
BRPI0507489A (pt) 2007-07-10
IL177242A0 (en) 2006-12-10
WO2005103083A2 (en) 2005-11-03
EP2511297A1 (en) 2012-10-17
DK1720907T3 (en) 2015-06-15
KR20140066259A (ko) 2014-05-30
HK1097859A1 (en) 2007-07-06
HRP20150641T1 (hr) 2015-07-17
PT2511297E (pt) 2015-08-24
ES2541489T3 (es) 2015-07-21
JP2016164198A (ja) 2016-09-08
EP2915820A1 (en) 2015-09-09
EP1720907A2 (en) 2006-11-15
KR20130126747A (ko) 2013-11-20
JP2012116856A (ja) 2012-06-21
DK2511297T3 (en) 2015-06-15
WO2005103083A8 (en) 2006-10-05
SG142330A1 (en) 2008-05-28
EP2511297B1 (en) 2015-04-08
JP2008504013A (ja) 2008-02-14
NZ548990A (en) 2009-06-26
CY1116458T1 (el) 2017-03-15
EP1720907B1 (en) 2015-04-08
ES2541436T3 (es) 2015-07-20
ME02245B (me) 2015-10-30
RS54056B1 (en) 2015-10-30
WO2005103083A3 (en) 2006-11-16
JP5926568B2 (ja) 2016-05-25
JP2015110597A (ja) 2015-06-18
NO20063986L (no) 2006-11-06
PL2511297T3 (pl) 2015-08-31

Similar Documents

Publication Publication Date Title
US9758590B2 (en) Anti-CD38 human antibodies and uses thereof
US11939395B2 (en) Generation and profiling of fully human HuCAL gold-derived therapeutic antibodies specific for human CD38
DK2511297T3 (en) Human anti-CD38 antibodies and their applications
US20090123950A1 (en) Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38
US9200061B2 (en) Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
RU2402568C2 (ru) Человеческие анти-cd38-антитела и их применение